Papadimitriou L, Butler J
Stony Brook University, Cardiology Division, Stony Brook, New York, USA.
Clin Pharmacol Ther. 2017 Aug;102(2):184-186. doi: 10.1002/cpt.734. Epub 2017 Jun 21.
Heart failure (HF) is a global epidemic, with a high mortality and morbidity burden. In such diseases, earlier access to lifesaving therapeutic regimens is imperative, and could be accomplished by improving the drug development and approval process, without jeopardizing patient safety. The US Food and Drug Administration (FDA) has already established mechanisms facilitating the latter, but further guidance to enhance and expedite the process holds promise to further improve patient outcomes.
心力衰竭（HF）是一种全球性疾病，具有很高的死亡率和发病率负担。对于这类疾病，尽早获得挽救生命的治疗方案至关重要，这可以通过改进药物研发和审批流程来实现，同时又不危及患者安全。美国食品药品监督管理局（FDA）已经建立了促进后者的机制，但进一步加强和加快这一流程的指导有望进一步改善患者预后。
